Key drivers included sample preparation technologies, the QIAcuity digital PCR platform and the QIAGEN Digital Insights bioinformatics business. QIAGEN achieved growth in the high single-digit percentage range for sample preparation consumables. However, headwinds continue to stem from weaker business with laboratory instruments in the US. Lower demand for tuberculosis tests in connection with US immigration procedures is also weighing on the momentum of QuantiFERON. The adjusted operating margin reached 29.4 per cent. Adjusted earnings per share of $0.62 were slightly above the company’s own forecast. For the full year, QIAGEN is maintaining its outlook and expects revenue growth of one to two per cent at constant exchange rates. For the second half of the year, the company is focusing, amongst other things, on new sample preparation systems and additional applications for QIAcuity. The figures also reveal a pattern in the life sciences market. Recurring revenue from consumables and digital solutions is currently performing more robustly than the more capital-intensive instrument business.
News from “QIAGEN” dated 5 August 2026